Skip to main content
LEAP THERAPEUTICS, INC. logo

LEAP THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LPTX ISIN · US52187K2006 LEI · 549300T31SMMJ2DDLI13 US Manufacturing
Open in API
Filings indexed 584 across all filing types
Latest filing 2020-01-03 Regulatory Filings
Country US United States of America
Listing US LPTX

About LEAP THERAPEUTICS, INC.

https://www.leaptx.com/

Leap Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics for cancer. Its most advanced clinical candidate, DKN-01 (sirexatamab), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, being developed for patients with esophagogastric, gynecologic, and colorectal cancers. The company's pipeline also includes FL-301, a monoclonal antibody targeting Claudin18.2 for gastric and pancreatic cancer, and FL-501, a preclinical antibody targeting the growth and differentiation factor 15 (GDF-15) protein.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated January 3, 2020, by Leap Therapeutics, Inc. It reports the entry into a material definitive agreement (an exclusive option and license agreement with BeiGene, Ltd.) and includes a press release about this event. The content focuses on a specific corporate event related to licensing and collaboration, which is typical for a current report on Form 8-K. There are no financial statements or comprehensive financial data presented, nor is this an annual or quarterly report. The document is not a proxy, earnings release, or management discussion. Therefore, the filing type corresponds to a Regulatory Filing (RNS) as a current report disclosing a material event under the Securities Exchange Act of 1934.
2020-01-03 English
FORM 8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a notice of non-compliance with Nasdaq listing requirements and a plan to regain compliance, as well as an announcement of a clinical study collaboration. The key event is the notice of delisting risk due to stockholders' equity falling below Nasdaq's minimum requirement. This matches the definition of a Delisting Announcement (DLST). The document is about 5676 characters, which is consistent with a typical 8-K filing length. Therefore, the classification is DLST with high confidence.
2019-11-22 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 14, 2019, by Leap Therapeutics, Inc. It announces the company's financial results for the quarter ended September 30, 2019, and includes a press release as an exhibit. The text explicitly states that the announcement is a press release of financial results, which is typical of an Earnings Release. The document does not contain detailed financial statements or comprehensive analysis, but rather a summary announcement of quarterly results. The length is 4233 characters, which is relatively short and consistent with an earnings release announcement rather than a full interim or annual report. Therefore, the document is best classified as an Earnings Release (ER).
2019-11-14 English
10-Q
Interim / Quarterly Report 9M 2019
2019-11-14 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Leap Therapeutics, Inc. It discloses Regulation FD Disclosure about a press release and a corporate poster presentation for a conference. The document does not contain financial statements or detailed financial data but rather announces the availability of a presentation and a press release. The document is short (4791 characters) and primarily serves as a disclosure notice rather than a full report. Therefore, it fits best as a Regulatory Filing (RNS) rather than a financial report or presentation itself.
2019-09-17 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the sale of common stock by a selling stockholder. It includes detailed information about the offering, risk factors, use of proceeds, plan of distribution, and corporate information. The document is not a financial report, earnings release, or management discussion but rather a registration and offering document for securities. This type of filing corresponds to a Capital/Financing Update as it relates to fundraising and capital structure changes through a stock offering. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual prospectus document itself. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2019-08-12 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.